TickerGuard
Buy Day today: Poor (57) Mixed market breadth · today: Nonfarm Payrolls (September)
VTRS

Viatris Inc

Healthcare · Drug Manufacturers - Specialty & Generic

17.50$ -1.5% vs. previous close Closing price · As of: Oct 1, 2026

Statements

Ratios

Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.

Tick rows to compare them in a chart (up to 4)

Ratios VTRS
Line item 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Valuation
32.5 25.5 34.7 21.3 86.0 18.4 16.1 20.9 23.8 25.4 20.2 – – 24.3 20.1 17.6 18.0 27.5 24.2 31.7 41.4 32.6 40.1 618.0 – – 6.5 238.3 – –
4.7 4.9 5.6 4.2 3.8 4.3 3.5 5.1 3.9 3.7 2.7 1.2 0.6 1.1 1.3 1.5 1.7 2.5 2.9 2.9 1.8 1.9 1.2 0.9 0.9 0.9 0.8 0.8 1.0 1.0
3.1 3.5 3.8 2.7 2.8 3.4 3.0 4.2 2.6 5.9 2.6 1.1 1.1 1.8 1.9 2.7 3.5 5.8 6.9 2.8 1.8 1.7 1.2 0.9 0.5 0.8 0.6 0.6 0.8 1.0
4.4 4.7 5.3 3.9 3.5 4.2 3.2 5.0 3.8 3.6 2.1 1.3 0.5 1.1 1.2 1.6 1.7 2.5 3.2 2.8 3.1 3.1 2.4 2.0 3.0 2.2 1.9 2.0 1.9 1.9
42.1 36.5 16.7 12.9 14.0 10.9 9.5 12.8 13.6 13.6 4.9 – 3.5 5.7 5.8 6.6 7.0 11.0 13.3 11.7 16.4 11.4 9.3 8.4 18.2 8.7 4.9 8.6 10.0 –
104.5 108.1 27.3 36.3 75.4 14.7 15.6 65.3 42.9 15.0 19.2 63.4 13.7 12.5 9.4 21.4 18.0 22.2 32.6 16.4 12.0 12.7 6.8 7.4 20.4 6.5 5.4 5.6 7.5 7.6
1.0% 0.9% 3.7% 2.8% 1.3% 6.8% 6.4% 1.5% 2.3% 6.7% 5.2% 1.6% 7.3% 8.0% 10.6% 4.7% 5.6% 4.5% 3.1% 6.1% 8.3% 7.9% 14.8% 13.5% 4.9% 15.4% 18.6% 17.8% 13.3% 13.2%
Margins
44.9% 49.6% 57.0% 58.7% 50.1% 56.5% 52.9% 55.5% 49.7% 49.9% 52.3% 40.1% 40.3% 40.7% 40.7% 41.8% 42.8% 44.0% 45.7% 44.7% 42.4% 40.2% 35.0% 33.9% 31.8% 31.2% 40.0% 41.7% 38.2% 35.1%
13.2% 18.4% 27.4% 28.2% 2.3% 35.8% 32.6% 36.0% 24.1% 22.9% 26.5% 12.8% 5.8% 10.3% 13.2% 16.4% 16.3% 16.4% 17.5% 15.5% 6.3% 12.1% 7.9% 6.2% -1.8% -0.2% 9.9% 5.0% 0.1% -18.6%
14.3% 19.1% 16.0% 19.5% 4.4% 23.6% 21.5% 24.3% 16.2% 14.7% 13.5% -52.2% -3.8% 4.6% 6.3% 8.8% 9.4% 9.0% 12.0% 9.0% 4.3% 5.8% 3.1% 0.1% -5.6% -7.1% 12.8% 0.4% -4.3% -24.6%
4.5% 4.5% 20.3% 11.4% 5.0% 29.5% 22.1% 7.8% 9.0% 24.9% 14.2% 2.0% 4.3% 8.8% 13.6% 7.2% 9.5% 11.2% 8.9% 17.5% 15.0% 15.0% 18.3% 12.2% 4.6% 14.0% 15.4% 15.1% 13.4% 13.5%
Returns
9.6% 13.5% 10.9% 12.8% 3.3% 18.6% 18.8% 20.2% 11.0% 23.4% 12.8% -44.6% -7.1% 7.4% 9.6% 15.4% 19.2% 21.2% 28.5% 8.7% 4.3% 5.2% 2.9% 0.1% -2.9% -6.2% 9.9% 0.3% -3.4% -23.9%
8.1% 11.9% 9.6% 11.5% 2.5% 16.1% 15.6% 17.8% 9.5% 9.9% 5.1% -13.4% -1.9% 2.2% 3.0% 4.6% 5.4% 4.1% 5.9% 3.8% 1.4% 1.9% 1.1% 0.1% -1.1% -2.3% 4.2% 0.1% -1.5% -9.5%
Balance Sheet & Debt
-109 -95 -173 -194 -224 -161 -257 -110 -136 -146 -1,019 66 -443 -238 -519 433 47 164 2,559 -236 14,474 14,369 13,430 12,273 25,087 22,456 18,086 17,214 13,392 13,175
-2.4 -1.4 -0.8 -0.8 -1.1 -0.4 -0.6 -0.2 -0.4 -0.4 -1.5 – -0.6 -0.3 -0.5 0.3 0.0 0.1 1.4 -0.1 6.9 4.4 4.6 4.6 12.6 5.0 2.8 4.9 4.7 –
84.8% 87.8% 87.8% 89.7% 77.3% 86.7% 82.9% 88.0% 86.4% 42.1% 39.8% 30.0% 26.5% 29.0% 31.2% 30.1% 28.0% 19.2% 20.6% 43.9% 32.0% 37.2% 37.2% 38.0% 37.3% 37.4% 42.1% 42.9% 44.9% 39.6%
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.1 0.0 0.2 0.1 0.2 0.9 0.1 1.4 1.1 1.1 1.1 1.1 1.1 0.9 0.9 0.8 1.0
Per Share
0.23 0.36 0.40 0.53 0.13 0.91 0.96 1.21 0.74 0.79 0.99 -5.90 -0.64 0.76 1.05 1.22 1.52 1.58 2.34 1.70 0.92 1.30 0.68 0.03 -1.11 -1.05 1.71 0.05 -0.53 -3.00
1.59 1.91 2.52 2.70 2.97 3.85 4.50 4.97 4.58 5.37 7.36 11.30 16.88 16.59 16.57 13.97 16.17 17.51 19.40 18.96 21.28 22.19 22.14 22.27 19.87 14.80 13.36 12.78 12.35 12.21
2.38 2.69 3.70 4.11 3.97 4.89 5.12 6.01 6.75 3.36 7.72 13.24 9.06 10.20 10.95 7.96 7.95 7.46 8.18 19.63 21.36 24.80 23.56 23.01 38.18 16.95 17.31 16.96 15.62 12.57
0.07 0.09 0.51 0.31 0.15 1.14 0.99 0.39 0.41 1.34 1.04 0.22 0.72 1.47 2.25 1.00 1.53 1.96 1.73 3.31 3.18 3.33 4.05 2.71 0.92 2.07 2.06 1.93 1.66 1.65

Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?